Orasi Medical provides neurological biomarkers based on electrical activity of the brain. Our flagship product, Orasi Index™ accelerates neurological and psychiatric drug development, reduces costs and improves outcomes, providing pharmaceutical companies invaluable insight by:
- Confirming the drug reaches the brain
- Identifying the most effective dose
- Selecting the best patients, and
- Measuring drug effect earlier and more accurately.
Orasi's biomarkers are being developed to help diagnosis and assess progression of CNS diseases such as Alzheimers disease, multiple sclerosis, tinnitus, schizophrenia, and depression. These additional magnetoencepholography (MEG) and electroencephalography (EEG) biomarkers will further improve drug development by supporting later stage clinical trials.
Orasi has the largest database of MEG brain scans, MEG biomarkers and supporting clinical data for an expanding range of drug signatures and disease patterns.
To learn more about Orasi Medical's products and services, please download our company summary by clicking on the image.